Department of Medicine

Department of Medicine

  Division of Hematology/Oncology

[Return To Index page]
photo Deborah L. Galson, PhD

Associate Professor of Medicine, Division of Hematology/Oncology

Associate Professor of Microbiology & Molecular Genetics

Member, UPCI

Member, Molecular and Cellular Cancer Biology Program

Director, Pittsburgh Center for Bone & Mineral Research

Member, McGowan Institute for Regenerative Medicine


Phone: 412-623-1112

Office: Hillman Cancer Center Research Pavilion, Rm 1.19b
5117 Centre Avenue
Pittsburgh, PA 15213
Phone: 412-623-1112
Fax: 412-623-1415
Administrative Assistant:
Dianna Fennel
Address: UPMC Hillman Cancer Center
Research Pavilion, 1.19a
Pittsburgh, PA
Phone: 412-623-1114
Fax: 412-623-1415
Education and Training
PhD, Brandeis University, 1984
B.S., Cornell University, 1976
Postdoctoral, Massachusetts Institute of Technology, 1990
Instructor, Harvard Medical School/Brigham & Women's Hospital, 1995
Research Interest
Investigate the regulation of differentiation starting from identifying the key transcriptional regulators outwards to reveal the important signal transduction pathways. We use this approach to investigate pathological changes in the bone microenvironment, particularly osteoclasts and osteoblasts, in Multiple Myeloma (MM) and Paget’s disease of bone. Our current studies focus on: 1) the mechanism by which Measles virus nucleocapsid protein (MVNP), which contributes to Paget’s disease of bone, activates cellular genes and alters osteoclast differentiation; 2) the mechanism of cooperation between MVNP and p62 (SQSTM1) with pagetic mutations (eg. p62P392L) to generate Paget's lesions; 3) the mechanism by which MM cells suppresses osteoblast differentiation by inducing epigenetic repression of Runx2; 4) the role of Gfi1 in regulating osteoblast and osteoclast differentiation and identification of cofactors; 5) the roles of the IKK family members TBK1, IKKe, and optineurin in inflammatory bone diseases. Our studies have resulted in the identification of novel potential therapeutic targets in the pathological bone microenvironment in MM-induced bone disease. The usefulness of inhibiting these targets is under investigation in preclinical studies.
For my complete bibliography, Click Here.
Selected Publications:
Sun Q, Sammut B, Wang FM, Kurihara N, Windle JJ, Roodman GD, Galson DL. TBK1 mediates critical effects of measles virus nucleocapsid protein (MVNP) on pagetic osteoclast formation. J Bone Miner Res. 2014; 29 (1): 90-102.
Teramachi J, Zhou H, Subler MA, Kitagawa Y, Galson DL, Dempster DW, Windle JJ, Kurihara N, Roodman G. Increased IL-6 expression in osteoclasts is necessary but not sufficient for the development of Paget's disease of bone. J Bone Miner Res. 2014; 29 (6): 1456-65.
Adamik J, Wang KZ, Unlu S, Su A-J, Tannahill GM, Galson DL, O’Neill LA, Auron PE. Distinct mechanisms for induction and tolerance regulate the immediate early genes encoding interleukin 1ß and Tumor Necrosis Factor alpha. PLoS One. 2013; in press June 19.
Zhu K, Jiao H, Li S, Cao H, Galson DL, Zhao Z, Zhao X, Lai Y, Fan J, Im H-J, Chen D, Xiao G. ATF4 promotes bone angiogenesis by increasing VEGF expression and release in the bone environment. J Bone Miner Res:. 2013; in press Apr 2: Epub2013May3.
Teramachi J, Hiruma Y, Ishizuka S, Ishizuka H, Brown JP, Michou L, Cao H, Galson DL, Subler MA, Zhou H, Dempster DW, Windle JJ, Roodman GD, Kurihara N. Role of ATF7-TAF12 interactions in the vitamin D response hypersensitivity of osteoclast precursors in Paget’s disease. J Bone Miner Res. 2013; 28: 1489-500.
Wang F-M, Sarmasik A, Hiruma Y, Sun Q, Sammut B, Windle JJ, Roodman GD, Galson DL. Measles virus nucleocapsid protein, a key contributor to Paget's disease, increases IL-6 expression via down-regulation of FoxO3/Sirt1 signaling. Bone. 2013; 53: 269-76.
D’Souza S, Del Prete D, Jin S, Sun Q, Huston, AJ, Kostov FE, Sammut B, Hong, C-S, Anderson JL, Patrene KD, Yu S, Velu CS, Xiao G, Grimes HL, Roodman GD, Galson DL. Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease. Blood. 2011; 118: 6871-80.
Wang F-M, Galson DL, Roodman GD, Ouyang H. Resveratrol triggers the pro-apoptotic endoplasmic reticulum stress response and represses the pro-survival XBP1 signaling in human multiple myeloma cells. Exp Hematology. 2011; 39: 999-1006.
Li S, Pal R, Monaghan SA, Schafer P, Ouyang H, Mapara M, Galson DL, Lentzsch S. IMiD® immunomodulatory compounds block C/EBPß translation through eIF4E downregulation resulting in inhibition of multiple myeloma. Blood. 2011; 117: 5157-65.
Kurihara N, Hiruma Y, Yamana K, Michou L, Rousseau C, Morissette J, Galson DL, Zhou H, Dempster DW, Windle JJ, Brown JP, Roodman GD. Contributions of the Measles virus nucleocapsid gene and the SQSTM1/p62P392L mutation to Paget’s disease. Cell Metabolism. 2011; 13: 23-34.
Notable Achievements
American Association of University Women Fellowship, 1982-1983
NIH Postdoctoral Fellowship (National Cancer Institute), 1984-1987
Eighth Annual Dept of Medicine Research Day Award-Junior Faculty Basic, 2010
Annual Meeting Program Committee, American Society for Bone and Mineral Reserach, 2003,2007,2013, 2016
Women in Bone and Mineral Research Committee, American Society for Bone and Mineral Research, 2005-2008
Membership Engagement and Education Committee, American Society for Bone and Mineral Research, 2012-2015
Finance Committee, American Society for Bone and Mineral Reserach, 2016-2019
NIH Skeletal Biology Development and Disease Study Section, 2014